41 results
DEFA14A
AMTI
Applied Molecular Transport Inc.
15 Dec 23
Additional proxy soliciting materials
4:06pm
” is amended and restated by replacing it with the following:
On February 10, 2023, Cyclo entered into an engagement letter with MTS to assist in identifying … and this engagement letter was terminated on September 14, 2023, with the indemnification provisions of the letter surviving such termination. MTS did
8-K
AMTI
Applied Molecular Transport Inc.
15 Dec 23
Other Events
4:05pm
of the Merger” is amended and restated by replacing it with the following:
On February 10, 2023, Cyclo entered into an engagement letter with MTS … for Cyclo in July 2023 and this engagement letter was terminated on September 14, 2023, with the indemnification provisions of the letter surviving
DEFM14A
AMTI
Applied Molecular Transport Inc.
21 Nov 23
Proxy related to merger
9:16am
engagement, biomarkers, patient selection, or other relevant criteria to be utilized in preclinical and clinical product candidate development … , to regain compliance with the Bid Price Requirement.
On February 10, 2023, Cyclo entered into an engagement letter with MTS to assist in identifying
425
AMTI
Applied Molecular Transport Inc.
21 Sep 23
Business combination disclosure
5:12pm
agency; and (vi) any notice required for termination of their engagement.
(f) Except as would not result in material liability, the Company has properly
8-K
EX-2.1
rx4s4sh
21 Sep 23
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
5:10pm
8-K
EX-10.1
9s24ksr
24 Jul 23
Departure of Directors or Certain Officers
4:01pm
8-K
EX-10.1
t0bu415t85d7zz
4 Mar 22
Departure of Directors or Certain Officers
6:06am